These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 26238981)

  • 1. Role of targeted therapy in combination with surgery in renal cell carcinoma.
    Bex A; Powles T; Karam JA
    Int J Urol; 2016 Jan; 23(1):5-12. PubMed ID: 26238981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of cytoreductive surgery in the era of targeted agents.
    Noe A; Stewart GD; Bex A
    Curr Opin Urol; 2015 Sep; 25(5):374-80. PubMed ID: 26075568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment strategies for advanced renal cell carcinoma: A new paradigm for surgical treatment.
    Tomita Y
    Int J Urol; 2016 Jan; 23(1):13-21. PubMed ID: 26347163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted therapy after complete resection of metastatic lesions in metastatic renal cell carcinoma.
    Park YH; Jung JW; Lee BK; Lee S; Jeong SJ; Byun SS; Lee SE
    Int J Urol; 2015 Feb; 22(2):153-7. PubMed ID: 25421791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy.
    Kwan KG; Kapoor A
    Curr Opin Support Palliat Care; 2009 Sep; 3(3):157-65. PubMed ID: 19528804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy.
    Rini BI; Campbell SC
    J Urol; 2007 Jun; 177(6):1978-84. PubMed ID: 17509276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integration of surgery and systemic therapy for renal cell carcinoma.
    Kenney PA; Wood CG
    Urol Clin North Am; 2012 May; 39(2):211-31, vii. PubMed ID: 22487764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [CYTOREDUCTIVE NEPHRECTOMY IN METASTATIC RENAL CELL CANCER].
    Nosov AK; Novik AV; Vorobiev AV; Samartseva EE; Reva SA; Baldueva IA; Lushina PA
    Vopr Onkol; 2015; 61(3):494-8. PubMed ID: 26242167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel targeted therapy for advanced renal carcinoma: trials in progress.
    Calabrò F; Sternberg CN
    Curr Opin Urol; 2010 Sep; 20(5):382-7. PubMed ID: 20625300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant Therapy for Locally Advanced Renal Cell Carcinoma.
    Westerman ME; Shapiro DD; Wood CG; Karam JA
    Urol Clin North Am; 2020 Aug; 47(3):329-343. PubMed ID: 32600535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of metastasectomy in renal cell carcinoma in the era of targeted therapy.
    Ljungberg B
    Curr Urol Rep; 2013 Feb; 14(1):19-25. PubMed ID: 23212738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma of variant histology.
    Alhalabi O; Karam JA; Tannir NM
    Curr Opin Urol; 2019 Sep; 29(5):521-525. PubMed ID: 31305271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgery for renal cell carcinoma metastases.
    Breau RH; Blute ML
    Curr Opin Urol; 2010 Sep; 20(5):375-81. PubMed ID: 20592612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome.
    Wood CG
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):697s-702s. PubMed ID: 17255296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
    Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
    J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-modal treatment for metastatic renal cancer: the role of surgery.
    Russo P
    World J Urol; 2010 Jun; 28(3):295-301. PubMed ID: 20364382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic therapy in the management of localized and locally advanced renal cell carcinoma: Current state and future perspectives.
    Berquist SW; Yim K; Ryan ST; Patel SH; Eldefrawy A; Cotta BH; Bradshaw AW; Meagher MF; Bindayi A; McKay RR; Autorino R; Staehler M; Derweesh IH
    Int J Urol; 2019 May; 26(5):532-542. PubMed ID: 30943578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma.
    Karam JA; Rini BI; Varella L; Garcia JA; Dreicer R; Choueiri TK; Jonasch E; Matin SF; Campbell SC; Wood CG; Tannir NM
    J Urol; 2011 Feb; 185(2):439-44. PubMed ID: 21167518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytoreductive nephrectomy in metastatic renal cell carcinoma.
    Margulis V; Matin SF; Wood CG
    Curr Opin Urol; 2008 Sep; 18(5):474-80. PubMed ID: 18670270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Survival following Initial Cytoreductive Nephrectomy versus Initial Targeted Therapy for Metastatic Renal Cell Carcinoma.
    Bhindi B; Habermann EB; Mason RJ; Costello BA; Pagliaro LC; Thompson RH; Leibovich BC; Boorjian SA
    J Urol; 2018 Sep; 200(3):528-534. PubMed ID: 29574109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.